Cancer is one of the most deadly diseases, highlighting the importance to develop novel therapeutics to improve the survival of patients. A new and very promising approach is cancer immunotherapy. Immune checkpoint blocking antibodies are achieving remarkable responses in a fraction of cancer patients across several tumour types. However, many patients do not respond or acquire resistance.
The Oncology and Cellular Immunology Laboratory is particularly interested in how innate immune cells contribute to resistance to current immunotherapies. Its team aims to understand the cellular and molecular mechanism to identify novel targets. For this, genetically engineered and transplantable mouse models of cancer, state-of-the art flow cytometry, imaging as well as next generation sequencing techniques are commonly used.